European Orthopedic Biomaterials Market is expected to reach € 376.7 Million by 2019, revels new report

The European orthopedic biomaterials market is expected to reach €376.7 million by 2019, with hyaluronic acid viscosupplementation as the largest segment.

The European orthopedic biomaterials market includes bone graft substitutes (BGS), hyaluronic acid (HA) viscosupplementation, bone morphogenetic protein (BMP) growth factor therapy and autologous chondrocyte implantation (ACI).

As the market continued to recover from the economic crisis, slow growth was often seen across different regions. The ACI market underwent drastic changes in 2012 due to modifications in the European Medicines Agency (EMA) regulations.

While autografts were still commonly used in 2012, easy accessibility and price declines have made bone graft substitute products an attractive option. Surgeons and patients alike have become increasingly interested in minimally invasive procedures, which greatly decrease the pain associated with bone graft procedures.

Scope: This report pertains to a forecast period of 10 years (2009 – 2019) for:

Austria, Belgium, Denmark, Finland, France, Germany, Italy, Luxembourg, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, U.K.

Report Contents:

• Competitor Analysis
• Identified Strategic Opportunities
• Market Overview by Segment & Country
• Trend Analysis by Segment & Country
• Market Drivers & Limiters
• Mergers & Acquisitions
• Customer Feedback and Market Monitoring

Main Segments Included:

• Bone Graft Substitute Market
• Allograft Bone Graft Substitute Market
• Synthetic Bone Graft Substitute Market
• Demineralized Bone Matrix Bone Graft Substitute Market
• Hyaluronic Acid Viscosupplementation Market
• Bone Morphogenetic Protein Growth Factor Market
• Autologous Chondrocyte Implantation Market

Sub-Segments Included:

• Allograft Cervical Spine Market
• Allograft Thoracolumbar Spine Market
• Allograft Trauma and Reconstruction Market
• Allograft Craniomaxillofacial Market
• Synthetic Cervical Spine Market
• Synthetic Thoracolumbar Spine Market
• Synthetic Trauma and Reconstruction Market
• Synthetic Craniomaxillofacial Market
• Cervical Spine Demineralized Bone Matrix Market
• Thoracolumbar Spine Demineralized Bone Matrix Market
• Trauma and Reconstruction Demineralized Bone Matrix Market
• Craniomaxillofacial Demineralized Bone Matrix Market

Spanning over 328 pages, “European Markets for Orthopedic Biomaterials” report includes European Orthopedic Biomaterials Market, Country Profiles, Bone Graft Substitute Market, Hyaluronic Acid Viscosupplementation Market, Bone Morphogenetic Protein Growth Factor Therapy Market, Autologous Chondrocyte Implantation Market. The report covers 34 companies; few are DePuy SynthesOlympus, Zimmer, Wright Medical, Smith & Nephew, RottaPharm, Fidia, Genzyme, Medtronic, TRB Chemedica, Laboratoire Genevrier, Stryker, RTI Biologics, Biomet, Croma-Pharma, TiGenix, Fin-Ceramica, Tedec-Meiji, Seikagaku.

For more information visit: http://www.marketresearchreports.com/idata-research/european-markets-orthopedic-biomaterials

Find all Pharmaceuticals and Healthcare reports under a single page

MarketResearchReports.com: Type 2 Diabetes Therapeutics Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019, New Report Launched

There is currently a large number of blood glucose-lowering drugs in the crowded type 2 diabetes market indicated for the treatment of chronically high blood glucose. The market is led by Lantus, which achieved global sales amounting to $6.4 billion in 2012.

Over the forecast period from 2012 to 2019, the safer, more efficacious newer classes of drug (GLP-1 agonists, DPP-4 Inhibitors and SGLT-2 inhibitors) are expected to capture substantial market shares, largely replacing older classes such as sulfonylureas and thiazolidinediones. Additionally, a variety of novel drugs belonging to these newer classes are due to enter the market, and are expected to offer a moderate improvement in terms of efficacy and safety. The price of these new therapies is expected to be high, but this is unlikely to hinder their uptake. As a result, as well as an overall increase in the prevalent population, publisher believes that the value of the global market has the potential to grow to reach $38.8 billion by 2019.

Scope

• A brief introduction to type 2 diabetes, including the symptoms, pathogenesis, risk factors and diagnosis
• Includes a heat map comparing major drugs in terms of safety, efficacy and dosing parameters.
• Comprehensive review of the pipeline for type 2 diabetes therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets.
• Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, trial duration and program failure rate analyses for each molecule type and mechanism of action
• Multi-scenario forecast data for the market up to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across key developed markets including the US, Japan, Germany, the UK, France, Italy and Spain
• Discussion of the drivers and barriers for market growth

Reasons to buy

• Understand the many different types of type 2 diabetes therapies on the market, from the older, established classes of treatment to newer, moderately superior types of drug, and their positions in the treatment algorithm
• Understand the strengths and weaknesses of each product
• Understand the scope of the pipeline, including which molecule types and mechanisms of action are prominent
• Observe trends in clinical trial duration and size amongst clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for type 2 diabetes therapeutics
• Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the type 2 diabetes therapeutics market.

Spanning over 125 pages, 16 tables and 40 figures “Type 2 Diabetes Therapeutics Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019” report provide in-depth analysis of major glucose-lowering drugs for type 2 diabetes, including analyses of their safety, efficacy, treatment patterns, strengths/weaknesses and overall commercial prospects.

In addition to covering the Key Marketed Products, Pipeline for Type 2 Diabetes, Market Forecast to 2019, Deals and Strategic Consolidations.

For more information visit: http://www.marketresearchreports.com/gbi-research/type-2-diabetes-therapeutics-market-2019-shifting-treatment-algorithm-and-intensified

Find all Pharmaceuticals and Healthcare reports under a single page

MarketResearchReports.com: Asthma Therapeutics Market is forecast to a projected value of $21.6 billion in 2019, Reveals New Report

The asthma market is forecast to grow marginally over the forecast period across the leading eight developed nations, from $16.6 billion in 2012 to a projected value of $21.6 billion in 2019. This growth is expected despite the generic erosion facing the leading brands, and is a consequence of new market entrants and a disease prevalence that continues to rise, albeit not at rates as high as have been seen in the past.

Some new, costly asthma therapies could be set to enter the asthma market, including GlaxoSmithKline’s (GSK’s) recently approved Relvar (fluticasone/vilanterol), and multiple monoclonal antibodies (mAbs). These include reslizumab, mepolizumab and lebrikizumab, which are being developed by Teva, GSK and Roche respectively.

The mAbs, in particular, have the potential to change the asthma treatment landscape, most notably with regards to severe forms of the disease. Although such therapy may only play the role of an alternative treatment in the asthma treatment algorithm, their ability to reduce exacerbation rates has strong clinical and commercial value.

The report assesses the current asthma market, and forecasts market trends to 2019, analyzing key drivers and barriers. The areas covered include the following:-

• A disease introduction, which defines the disease, including symptoms, diagnosis and treatment
• Analysis of the landscape of the asthma market, including a comparison of the efficacy and safety of the most prominent brands.
• An in-depth forecasting model for the asthma market, which considers the current marketed therapies, in addition to the potential market entry of new products. The model consists of a projected outcome, with high and low variance results, depending on the potential performance of pipeline therapies.
• Analysis of strategic consolidations within the asthma indication, including co-development and licensing agreements
• An overview of the drivers and barriers for the asthma market

Reasons to buy

Primarily, the report will enable clients to establish a strong understanding of the asthma indication, helping to identify and understand market opportunities and the emerging competitive environment. It will also enable you to:-

• Understand the asthma pipeline and the factors that indicate that it is becoming more innovative. This is highlighted by the presence of numerous biologics in the pipeline, which look set to have a major impact upon the asthma market.
• Observe detailed profiles for promising pipeline products, including revenue forecasts, and gain insights into how they are likely to compete in the market and who their main competitors will be.
• Follow the trends in asthma clinical trial size and duration in relation to industry averages. In addition, the report will enable you to assess the potential risk of future developmental programs for asthma therapeutics, depending on the mechanism of action, by considering the recorded clinical trial failure rates.
• Observe the potential growth patterns expected for the asthma market over the forecast period, and identify which countries are expected to contribute the most to this growth.

Spanning over 106 pages, 21 tables and 49 figures “Asthma Therapeutics Market to 2019 - Breakthrough Biologics to Enhance Treatment of Severe Asthma and Drive Market Growth” report provide Detailed analysis of the asthma pipeline, including, among other parameters, details of drug distribution by phase, molecule type and mechanism of action. The asthma clinical trial landscape is then analyzed, with a particular emphasis on failure rates across phases as well as trends in clinical trial size and duration, and by mechanism of action. This section also includes single-product forecasts for the most promising pipeline drugs.

In addition to covering the Marketed Products, Asthma Pipeline, Market Forecast to 2019, Strategic Consolidations.

For more information visit: http://www.marketresearchreports.com/gbi-research/asthma-therapeutics-market-2019-breakthrough-biologics-enhance-treatment-severe-asthma

Find all Healthcare reports under a single page

MarketResearchReports.com: Computed Tomography Systems Market to 2019 - Lower Radiation Dose and Improved Workflow in Advanced CT Systems to Increase Adoption Rates, New Report Launched

Computed Tomography Systems Market to 2019 Lower Radiation Dose and Improved Workflow in Advanced CT Systems to Increase Adoption Rates report looks at the market, competitive landscape, and trends for three computed tomography systems segments: high slice computed tomography systems, mid slice computed tomography systems and low slice computed tomography systems.

Report also reviews the competitive landscape and the details of important M&A deals. It is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by publisher team of industry experts.

Scope

• Key geographies of the US, Canada, the UK, Germany, France, Italy, Spain, Japan, China, India, Australia and Brazil
• Information on market size for three computed tomography systems segments: high slice computed tomography systems, mid slice computed tomography systems and low slice computed tomography systems.
• Annualized market revenue data forecast to 2019 and company share data for 2012
• Qualitative analysis of key trends in the computed tomography systems market
• Information on the leading market players, the competitive landscape, and the leading technologies
• Information on key players: GE Healthcare, Siemens Healthcare, Toshiba Medical Systems Corporation, Philips Healthcare, Hitachi Medical Corporation and Neusoft Medical Systems Co., Ltd.

Reasons to buy

• Develop business strategies by understanding the trends and developments driving the global computed tomography systems market
• Design and enhance your product development, marketing, and sales strategies
• Exploit M&A opportunities by identifying the market players with the most innovative pipelines
• Develop market-entry and market-expansion strategies
• Identify the key players best positioned to take advantage of emerging-market opportunities
• Exploit in-licensing and out-licensing opportunities by identifying the products most likely to ensure a robust return
• Identify, understand and capitalize on the next big thing in the computed tomography systems market landscape
• Make more informed business decisions from the insightful and in-depth analysis of the global computed tomography systems market and the factors shaping it

Spanning over 85 pages, 49 tables and 45 figures “Computed Tomography Systems Market to 2019 - Lower Radiation Dose and Improved Workflow in Advanced CT Systems to Increase Adoption Rates” report provides comprehensive information on the key trends affecting these segments and analyzes the market dynamics. For more information visit: http://www.marketresearchreports.com/gbi-research/computed-tomography-systems-market-2019-lower-radiation-dose-and-improved-workflow

In addition to covering the Computed Tomography Systems: Overview, Computed Tomography Systems: Market Characterization, Global Computed Tomography Systems Market: Segment Analysis and Forecasts, Global Computed Tomography Systems Market: Country Analysis and Forecasts, Global Computed Tomography Systems Market: Reimbursement Trends, Global Computed Tomography Systems Market: Distribution System, Global Computed Tomography Systems Market: Company Profiles, Global Computed Tomography Systems Market: Product Pipeline Analysis, Global Computed Tomography Systems Market: Consolidation Landscape. The report covers 6 companies - GE Healthcare, Siemens Healthcare, Toshiba Medical Systems Corporation, Philips Healthcare, Hitachi Medical Corporation and Neusoft Medical Systems Co., Ltd.

Find all Pharmaceuticals and Healthcare reports under a single page

MarketResearchReports.com: Mammography Equipment Market to 2019 - Growth Driven by Technical Advances in Digital Radiography that Enhance Workflow and Improve Breast Cancer Detection, New Report Launched

Mammography Equipment Market to 2019 - Growth Driven by Technical Advances in Digital Radiography that Enhance Workflow and Improve Breast Cancer Detection report looks at the market, competitive landscape, and trends for the two mammography equipment market segments: digital radiography mammography equipment and film-screen mammography equipment.

The report also reviews the competitive landscape, analyzes each segment’s pipeline products and gives details of important Merger and Acquisition (M&A) deals. It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by publisher team of industry experts.

Scope

• Key geographies: the US, Canada, the UK, Germany, France, Italy, Spain, Japan, China, India, Australia and Brazil
• Information on market size for the two mammography equipment market segments: full-field digital mammography equipment and film-screen mammography equipment
• Annualized market revenue data forecast to 2019 and company share data for 2012
• Qualitative analysis of key trends in the mammography equipment market
• Information on the competitive landscape, and the leading technologies of key players: Hologic, GE Healthcare, Siemens Healthcare, Philips Healthcare and FujiFilm Holdings Corporation
• Information on reimbursement trends and market access for key countries

Reasons to buy

• Develop business strategies by understanding the trends and developments driving the global mammography equipment market
• Design and enhance your product development, marketing, and sales strategies
• Exploit M&A opportunities by identifying the market players with the most innovative pipelines
• Develop market-entry and market-expansion strategies
• Identify the key players best-positioned to take advantage of the emerging market opportunities
• Exploit in-licensing and out-licensing opportunities by identifying the products most likely to ensure a robust return
• Identify, understand and capitalize on the next big thing in the mammography equipment market landscape
• Make more informed business decisions from insightful and in-depth analysis of the global mammography equipment market and the factors shaping it

Spanning over 79 pages, 38 tables and 39 figures “Mammography Equipment Market to 2019 - Growth Driven by Technical Advances in Digital Radiography that Enhance Workflow and Improve Breast Cancer Detection” report provides comprehensive information on the key trends affecting these segments, and key analytical content on the market dynamics. For more information visit: http://www.marketresearchreports.com/gbi-research/mammography-equipment-market-2019-growth-driven-technical-advances-digital-radiography

In addition to covering the Market Access – Regulatory Process, Distribution and Supply Chain, Reimbursement Trends, Global Mammography Equipment Market: Market Characterization, Global Mammography Equipment Market: Country Analysis, Global Mammography Equipment Market: Cost and Efficacy Analysis, Global Mammography Equipment Market: Comparison of DR mammography systems, Global Mammography Equipment Market: Key Company Profiles, Global Mammography Equipment Market: Pipeline Analysis, Global Mammography Equipment Market: Consolidation Landscape. The report covers 5 companies Hologic, Inc., GE Healthcare, Siemens Healthcare, Fujifilm Holdings Corporation and Philips Healthcare.

Find all Medical Devices reports under a single page

MarketResearchReports.com: Competitor Analysis: Staphylococcus aureus Vaccines and Therapeutics (Antibodies, Antibiotics, Anti-Infectives), New Report Launched

Novel Prophylactic and Therapeutic Approaches to Manage Staphylococcus aureus (S. aureus) Infections

Staphylococcus aureus disease is the leading cause of surgical site infections and infections that arise within hospital Intensive Care Units. Despite a clear and growing medical need, the pipeline for new antibiotics is drying up. Many pharmaceutical companies have abandoned antimicrobial research. In the meantime, bacteria are becoming more resistant to current antibiotics, with fewer new drugs being approved.

The present Competitive Intelligence Report about prophylaxis and therapy of S. aureus infections provides a competitor evaluation in the field of new molecules for prevention or treatment of Staphylococcus aureus infections as of October 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Staphylococcal aureus infections represent an enormous burden to public health systems. Traditionally restricted to the hospital setting as nosocomial infections, highly virulent strains have recently emerged in outside healthcare settings. Together with the increasing resistance to many antibacterials in a wide variety of staphylococcal strains, development of vaccines or specific and potent therapies for staphylococcal diseases raised increasing interest . Finding a vaccine for staphylococci is not trivial, as protective immunity to staphylococcal infections does not appear to exist at a significant degree. Promising results from novel approaches based on the combination of systematically selected antigens have been reported.

Passive immunotherapy with monoclonal therapeutic antibodies against S.aureus is another means to approach specific therapy of staphylococcal. While anti-staphylococcal purified polyclonal immunoglobulins are not recommended for prevention of staphylococcal infections in preterm or VLBW neonates, monoclonal antibodies are currently emerging and are in early development. Although not specific, bactericidal proteins and peptides with activity against S. aureus are in preclinical and clinical development. More targeted and improved antibiotics are also in development.

The report lists company-specific R&D pipelines of S. aureus vaccines and therapeutics. Competitor projects are listed in a tabular format providing information on:

• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product Category,
• Indication,
• R&D Stage

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Spanning over 92 pages, “Competitor Analysis: Staphylococcus aureus Vaccines and Therapeutics (Antibodies, Antibiotics, Anti-Infectives)” report includes a compilation of currently active projects in research and development of antibodies, proteins, peptides, vaccines and small molecules for prevention and  treatment of Staphylococcus aureus infections. For more information visit:  http://www.marketresearchreports.com/la-merie-publishing/competitor-analysis-staphylococcus-aureus-vaccines-and-therapeutics-antibodies

In addition to covering the S. aureus Vaccines, S. aureus Antibodies, S. aureus Antibiotics, S. aureus Antiseptics & Anti-Infectives, Corporate S. aureus Vaccines & Therapeutics R&D Pipelines.

Find all Pharmaceuticals and Healthcare reports under a single page

MarketResearchReports.com: The Engineered T-Cell Receptor in Fusion Proteins, Antibodies and Cells: Emerging Opportunities for the Biopharmaceutical Industry, New Report Launched

A comparative analysis and assessment of TCR technologies, pipelines and companies from an industry perspective

Therapeutic monoclonal antibodies have become an increasingly successful treatment modality with sales of US$ 65 bln in the year 2012 and with an average (continuous) annual growth rate from 2006 to 2012 of 18.9%. While antibody technologies are steadily evolving, the spectrum of druggable targets for monoclonal antibodies has remained limited to extracellular antigens, albeit including proteins, carbohydrates and glycolipids.

Access to druggable, IP-protected and validated new targets is a major bottleneck in the biopharmaceutical industry. Technologies which can deliver both new targets and the corresponding treatment modality, can expect significant financial acknowledgement.

The T-cell receptor (TCR) has recently emerged as a means to target peptide antigens derived from intracellular proteins, however, in a major histocompatibility complex (MHC)-restricted manner.  The first companies have overcome significant technical hurdles in putting together a library of viable new TCR-targeted antigens and establish the corresponding standardized protein- and cell-based therapeutic frameworks.

This report entitled, “The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry” published in Ocotber 2013 describes chances and pitfals in exploiting the opportunities which offers the engineered T-cell receptor as integral part of fusion proteins, antibodies and cellular products. The key success factors are highlighted, the technical challenges described and solutions presented.

Benefits from the report:

• Identify players in the field, from industry and academia;
• Find out which TCR technologies are valued by Big Pharma and Biotech;
• Understand the value of intracellular antigens targeted by the TCR;
• Recognize the challenges of TCR-based therapeutics and their solutions;
• Learn which TCR-based therapeutics are attractive for partnering;
• Find out which TCR therapeutic approaches are not yet tapped.

Spanning over 84 pages and 5 table, “The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry” report provides information on market overview, drivers and challenge, competition and key trends.

In addition to covering the The T-Cell Receptor, TCR Fusion Proteins, TCR-Like (TCRL) Antibodies, TCR-Transfected T-Cells, Artificial TCR T-Cells: Chimeric Antigen Receptor (CAR) T-Cells, Tumor-Infiltrating Lymphocytes (TILs), Opportunity Analysis for TCR-based Products and Technologies, Corporate R&D Pipelines.

For more information visit: http://www.marketresearchreports.com/la-merie-publishing/engineered-t-cell-receptor-fusion-proteins-antibodies-cells-emerging

Find all Therapeutic reports under a single page